Navigation Links
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients

rograms, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of Public Relations, Phone: (604) 822-0305 or 1-888-822-0305, Fax: (604) 822-0302, E-mail: , Internet: www.chemokine.net; Equicom Group, Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext. 233, Fax: (416) 815-0080, E-mail: devans@chemokine.net jlongo@equicomgroup.com

CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of PublicRelations, Phone: (604) 822-0305 or 1-888-822-0305, Fax: (604) 822-0302,E-mail: , Internet: www.chemokine.net; Equicom Group,Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext. 233, Fax:(416) 815-0080, E-mail: devans@chemokine.net jlongo@equicomgroup.com

Ticker Symbol: (Toronto:CTI.),(NASDAQ-OTCBB:CHKT)

'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... 2014 Research and Markets  has announced ... Repair Devices Market 2014-2018" report to their offering. ... of cells that connect, support, or surround bones. There ... tendons, ligaments, cartilage, fascia, and other fibrous tissues. Repetitive ... with age result in wear and tear in these ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
(Date:8/30/2014)... The Plastic Surgery Group (PSG) is one ... in the U.S. to provide clients with Vanquish, a ... waists with deep-tissue heating. , Unlike Cryotherapy which kills ... more inclusive to target large sections of desired weight ... about one inch away from their body while the ...
(Date:8/30/2014)... The establishment and creation of Ideal ... of the main strategies of the Church of ... around the world. , Architecturally stellar buildings with ... and trainers deliver L. Ron Hubbard's spiritual technology ... demonstrate that significant reduction in crime, major decrease ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country ... being diagnosed with the Alzheimer’s, inspired Seniors Guide writers to ... The movie, out on October 14, 2014, shows a ... of the disease – which inspires a final tour from ...
(Date:8/30/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 ... for broken bones or other orthopedic trauma shops around for ... Less-educated patients and patients who had used narcotic painkillers previously ... study lead author Dr. Brent Morris, a shoulder and neck ... that doctors aren,t talking to one another about the painkiller ...
(Date:8/30/2014)... of colchicine, a plant-based medication commonly used to ... mixed results in reducing potential complications from this ... risk of gastrointestinal adverse effects, according to a ... is being released early online to coincide with ... Congress. , Common complications after cardiac surgery include ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2
... 31 Previous studies have shown that hepatitis C ... African Americans than in whites. However, researchers demonstrate in ... meeting of the American Association for the Study of ... in that recurrent HCV in the transplanted liver progresses ...
... five times more lethal than other strains and has shown ... used to treat MRSA, according to a Henry Ford Hospital ... patients infected with the strain died within 30 days compared ... The average 30-day mortality rate for MRSA bloodstream ...
... with low body fat are at increased risk of ... body fat percentage, according to research being presented at ... Scientific Exposition in San Diego. "Our study indicates ... comments Kamyar Kalantar-Zadeh, PhD (LABioMed at Harbor-UCLA). "The results ...
... World AIDS Day 2008 Campaign, AHF/Cambodia CARES and Cambodian Partners ... PHNOM PENH, Cambodia, Oct. 31 As part of an ... in observance of the Testing Millions ... inaugural testing effort during the annual Water Festival, which marks ...
... Ford Hospital study found that hepatitis B does not increase the ... contributing factor. The results contradict a previous study in ... B infection. Hepatitis B is an inflammation of the liver caused ... the American Association for the Study of Liver Diseases, Annual Meeting ...
... the most seriously ill, experts say , SATURDAY, Oct. 31 ... appears to double the risk of stroke in patients with ... life, a new study finds. , Darbepoetin alfa, marketed ... often prescribed for diabetic patients with chronic kidney disease and ...
Cached Medicine News:Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 2Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 3Health News:Henry Ford Hospital study: A MRSA strain linked to high death rates 2Health News:For dialysis patients, skinny is dangerous 2Health News:Cambodia: World AIDS Day HIV Campaign, 'Testing Millions,' to Again Launch During Cambodia's National Water Festival 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: